ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

BMS Award Honors Jordan; Matthews Media Wins $23 Million Contract From MCI.

April 6, 2001

FDA Invites Ad Hoc Consumer Reps To ODAC Meetings

February 17, 1995

In Brief: New RFA, Program Announcements Coming Up Soon From BCDB for Radiation, Breast Cancer Studies

December 7, 1979

Nevins Reverses Position, Claims Potti Manipulated Data For Basis of Clinical Trials

February 17, 2012

Advocacy: Journal Club Leader Sought By NBCC

August 22, 1997

Lifestyle Changes Common After Cancer Diagnosis

August 26, 2005